An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy in Patients With Acromegaly
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Cimdelirsen (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 04 Jun 2023 Status changed from active, no longer recruiting to completed.
- 29 May 2023 This trial has been completed in Hungary (End Date: 04 May 2023), according to European Clinical Trials Database record.
- 04 Aug 2022 Planned End Date changed from 1 Aug 2023 to 1 Oct 2023.